Electroconvulsive therapy and the chronic use of pseudocholinesterase-inhibitor (echothiophate iodide) eye drops for glaucoma. A case report.
A case is presented in which a patient who required treatment with electroconvulsive therapy had a history of being treated with pseudocholinesterase-inhibitor eye drops (echothiophate iodide) for glaucoma. As treatment with this antiglaucoma agent contraindicated the use of succinylcholine for a minimum of 10-14 days, the short-acting nondepolarizing agent atracurium was employed instead. The anesthetic management of this patient is described as a guide for clinicians facing similar clinical situations.
Messer
G J
GJ
Medical Psychiatry Unit, Emory University Hospital, Atlanta, Georgia.
Stoudemire
A
A
Knos
G
G
Johnson
G C
GC
D000368:Aged; D000369:Aged, 80 and over; D001279:Atracurium / Q000494:pharmacology / Q000627:therapeutic use*; D002091:Butyrylcholinesterase / Q000097:blood; D000075202:Contraindications; D003866:Depressive Disorder / Q000150:complications / Q000628:therapy*; D004456:Echothiophate Iodide / Q000494:pharmacology; D004565:Electroconvulsive Therapy; D005260:Female; D005901:Glaucoma / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D013390:Succinylcholine / Q000494:pharmacology
D001279:Atracurium; D004456:Echothiophate Iodide; D002091:Butyrylcholinesterase; D013390:Succinylcholine